BLRX - BioLineRx - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

930.2M

Cash

28.17M

Avg Qtr Burn

-7.175M

Short % of Float

0.01%

Insider Ownership

8.54%

Institutional Own.

1.76%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
APHEXDA®(Motixafortide )(BL-8040) (CXCR4 antagonist) Details Multiple myeloma, Stem cell mobilization	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Motixafortide (BL-8040) w/ zimberelimab Details Pancreatic cancer, Cancer, Solid tumor/s	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Motixafortide (BL-8040) w/ cemiplimab Details Cancer, Solid tumor/s, Pancreatic cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Motixafortide (BL-8040) +/- natalizumab Details Cancer, Sickle cell disease, Blood disorder	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Motixafortide (BL-8040) (CXCR4 antagonist) Details Pancreatic cancer, Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Motixafortide (BL-8040) (CXCR4 antagonist) Details Acute myeloid leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AGI-134 Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.